nach oben

Neurological Sciences

Erschienen in:

25.02.2019 | Original Article

Correlations of serum cystatin C level and gene polymorphism with vascular cognitive impairment after acute cerebral infarction

verfasst von: Qiong Zeng, Zhihua Huang, Liling Wei, Jingnian Fang, Kun Lin

Erschienen in: Neurological Sciences | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to explore the possible correlations of serum cystatin C level and cystatin C gene (CST3) polymorphism with vascular cognitive impairment in patients who had acute cerebral infarction.

Methods

A total of 152 patients with acute cerebral infarction were recruited in this case-control study. Patients were divided into vascular cognitive impairment (VCI) group (n = 71) and cognitive impairment no dementia (CIND) group (n = 81). The serum concentrations of cystatin C were measured with immunoturbidimetric assay while the gene polymorphisms of CST3 were determined by technique polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Results

In the VCI group, serum cystatin C level was significantly higher than that in the control group. The frequency of the B allele was found to be higher in the VCI group as compared with that of the CIND group (18.5% vs 7.7%, p = 0.006). In logistic regression analysis, significant associations of VCI with high serum cystatin C level (OR 3.837 (1.176–12.520), p = 0.026) and CST3 B allele (OR 2.038 (1.048–3.963), p = 0.036) were also found.

Conclusions

A high cystatin C level and CST3 B allele confer risks for VCI after acute cerebral infarction. It is probable that measurement of the serum cystatin C level and detection of CST3 gene polymorphism would aid in the early diagnosis of VCI, but further studies are warranted.

Zeng Q, Lin K, Yao M, Wei L (2015) Significant correlation between cystatin C, cerebral infarction, and potential biomarker for increased risk of stroke. Curr Neurovasc Res 12(1):40–46CrossRefPubMed

Zeng Q, Wei L, Fang J, Li H, Lin K (2017) The correlation between dynamic changes of cystatin C levels and the severity and prognosis of cerebral infarction. J Shantou Univ Med Coll 12(4):206–207

Ghidoni R, Benussi L, Glionna M, Desenzani S, Albertini V, Levy E, Emanuele E, Binetti G (2010) Plasma Cys C and risk of developing Alzheimer’s disease in subjects with mild cognitive impairment. J Alzheimers Dis

Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B, Levy E (2004) Binding of Cys C to Alzheimer’s amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25:1033–1043CrossRefPubMed

Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B, Tagliavini F (2001) Codeposition of Cys C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 60:94–104CrossRefPubMed

Deng A, Irizarry MC, Nitsch RM, Growdon JH, Rebeck GW (2001) Elevation of Cys C in susceptible neurons in Alzheimer’s disease. Am J Pathol 159:1061–1068CrossRefPubMedPubMedCentral

Chuo LJ, Sheu WH, Pai MC, Kuo YM (2007) Genotype and plasma concentration of Cys C in patients with lateonset Alzheimer disease. Dement Geriatr Cogn Disord 23:251–257CrossRefPubMed

Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M (2007) Cys C modulates cerebral beta-amyloidosis. Nat Genet 39:1437–1439CrossRefPubMed

Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, Levy E (2007) Cys C inhibits amyloid-beta deposition in Alzheimer’s disease mouse models. Nat Genet 39:1440–1442CrossRefPubMed

10.

Ghidoni R, Benussi L, Glionna M, Desenzani S, Albertini V, Levy E, Emanuele E, Binetti G (2010) Plasma cystatin C and risk of developing Alzheimer’s disease in subjects with mild cognitive impairment. J Alzheimers Dis 22(3):985–991CrossRefPubMed

11.

Hu WD, Chen J, Mao CJ, Feng P, Yang YP, Luo WF, Liu CF (2016 Sep) Elevated cystatin C levels are associated with cognitive impairment and progression of Parkinson disease. Cogn Behav Neurol 29(3):144–149CrossRefPubMed

12.

Chen WW, Cheng X, Zhang X, Zhang QS, Sun HQ, Huang WJ, Xie ZY (2015 Aug) The expression features of serum cystatin C and homocysteine of Parkinson’s disease with mild cognitive dysfunction. Eur Rev Med Pharmacol Sci 19(16):2957–2963PubMed

13.

Yaffe K, Kurella-Tamura M, Ackerson L, Hoang TD, Anderson AH, Duckworth M, Go AS, Krousel-Wood M, Kusek JW, Lash JP, Ojo A, Robinson N, Sehgal AR, Sondheimer JH, Steigerwalt S, Townsend RR, the CRIC Study Investigators (2014 Sep) Higher levels of cystatin C are associated with worse cognitive function in older adults with chronic kidney disease: the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc 62(9):1623–1629CrossRefPubMedPubMedCentral

14.

Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S, Atkinson H, Windham BG, Kurella-Tamura M, Health ABC Study (2008) Cystatin-C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol 63(6):798–802CrossRefPubMedPubMedCentral

15.

Benussi L, Ghidoni R, Steinhoff T, Alberici A, Villa A, Mazzoli F, Nicosia F, Barbiero L, Broglio L, Feudatari E, Signorini S, Finckh U, Nitsch RM, Binetti G (2003) Alzheimer disease-associated Cys C variant undergoes impaired secretion. Neurobiol Dis 13:15–21CrossRefPubMed

16.

American Psychiatric Association (2013) Diagnostic and statistical manual ofMental disorders, 5th edn. American PsychiatricPress, Washington DCCrossRef

17.

Diciotti S, Orsolini S, Salvadori E, Tuscany investigators VMCI (2017) Resting state fMRI regional homogeneity correlates with cognition measures in subcortical vascular cognitive impairment. J Neurol Sci 15(373):1–6CrossRef

18.

Chen KL, Xu Y, Chu AQ, Ding D, Liang XN, Nasreddine ZS, Dong Q, Hong Z, Zhao QH, Guo QH (2016) Validation of the Chinese version of Montreal cognitive assessment basic for screening mild cognitive impairment. J Am Geriatr Soc 64(12):e285–e290CrossRefPubMed

19.

Lin J, Wang X, Dong F, du Y, Shen J, Ding S, Wang L, Ye M, Wang Y, Xia N, Zheng R, Chen H, Xu H (2018) Validation of the Chinese version of the Hamilton Rating Scale for Depression in adults with epilepsy. Epilepsy Behav 89:148–152CrossRefPubMed

20.

Wei Y, Wei YK, Zhu J (2017) Early markers of kidney dysfunction and cognitive impairment among older adults. J Neurol Sci 375:209–214CrossRefPubMed

21.

Tizon B, Ribe EM, Mi W, Troy CM, Levy E (2010) Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis 19(3):885–894CrossRefPubMedPubMedCentral

22.

Ghidoni R, Paterlini A, Albertini V et al (2011) Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer’s disease. Neurobiol Aging 32(8):1435–1442CrossRefPubMed

23.

Liang X, Nagai A, Terashima M et al (2011) Cystatin C induces apoptosis and tyrosine hydroxylase gene expression through JNK-dependent pathway in neuronal cells. Neurosci Lett 496(2):100–105CrossRefPubMed

24.

Tizon B, Sahoo S, Yu H et al (2010) Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS One 5(3):e9819CrossRefPubMedPubMedCentral

25.

Nagai A, Ryu JK, Terashima M, Tanigawa Y, Wakabayashi K, McLarnon JG, Kobayashi S, Masuda J, Kim SU (2005) Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res 1066:120–128CrossRefPubMed

26.

Slinin Y, Peters KW, Ishani A, Yaffe K, Fink HA, Stone KL, Steffes M, Ensrud KE, for the Study of Osteoporotic Fractures (2015) Cystatin C and cognitive impairment 10 years later in older women. J Gerontol A Biol Sci Med Sci 70(6):771–778CrossRefPubMed

27.

Sundelöf J, ArnlSv J, Ingelsson E et al (2008) Serum cystatin C and the risk of Alzheimer’s disease in elderly men. Neurology 71(14):1072–1079CrossRefPubMedPubMedCentral

28.

Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, Janka Z (2000) Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer’s dementia. Acta Neurol Scand 101:279–282CrossRefPubMed

29.

Zerovnik E (2009) The emerging role of cystatins in Alzheimer’s disease. Bioessays 31(6):597–599CrossRefPubMed

30.

Levy E (2008) Cys C: a potential target for Alzheimer’s treatment. Expert Rev Neurother 8:687–689CrossRefPubMed

31.

Tobin KA, Holven KB, Retterstøl K (2009) Cys C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: effect of treatment with B-vitamins. Br J Nutr 102:1783–1789CrossRefPubMed

32.

Bertram L, Mc Queen MB, Mullin K et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the Alz Gene database. Nat Genet 39(1):17–23CrossRef

33.

Benussi L, Ghidoni R, Steinhoff T, Alberici A, Villa A, Mazzoli F, Nicosia F, Barbiero L, Broglio L, Feudatari E, Signorini S, Finckh U, Nitsch RM, Binetti G (2003) Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 13:15–21CrossRefPubMed

34.

Crawford FC, Freeman MJ, Schinka JA, Abdullah LI, Gold M, Hartman R, Krivian K, Morris MD, Richards D, Duara R, Anand R, Mullan MJ (2000) A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease. Neurology 55:763–768CrossRefPubMed

35.

Maruyama H, Izumi Y, Oda M, Torii T, Morino H, Toji H, Sasaki K, Terasawa H, Nakamura S, Kawakami H (2001) Lack of an association between cystatin C gene polymorphisms in Japanese patients with Alzheimer’s disease. Neurology 57:337–339CrossRefPubMed

36.

Dodel RC, Du Y, Depboylu C et al (2002) A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD. Neurology 58(4):664CrossRefPubMed

37.

Monastero R, Camarda C, Cefalu AB et al (2005) No association between the cystatin C gene polymorphism and Alzheimer’s disease: a case-control study in an Italian population. J Alzheimers Dis 7(4):291–295CrossRefPubMed

38.

Hua Y, Zhao H, Lu X et al (2012) Meta-analysis of the cystatin C (CST3) gene G73A polymorphism and susceptibility to Alzheimer’s disease. Int J Neurosci 122(8):431–438CrossRefPubMed

39.

Strfilberg F, Henning P, Gjertsson I et al (2013) Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling. FASEB J 27(7):2687–2701CrossRef

40.

Cozlea DL, Farcas DM, Nagy A et al (2013) The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J 39(4):225–231PubMedPubMedCentral

Titel: Correlations of serum cystatin C level and gene polymorphism with vascular cognitive impairment after acute cerebral infarction
verfasst von: Qiong Zeng
Zhihua Huang
Liling Wei
Jingnian Fang
Kun Lin
Publikationsdatum: 25.02.2019
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 5/2019
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-03777-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Correlations of serum cystatin C level and gene polymorphism with vascular cognitive impairment after acute cerebral infarction

Abstract

Background

Methods

Results

Conclusions

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Bilateral trigeminal root entry zone enhancement in MOG-IgG-associated brainstem encephalitis

Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: a prospective double-blind randomized clinical trial

Association of uric acid with stenosis of intracranial and extracranial arteries in elderly patients with cerebral infarction

Methylation of cation–chloride cotransporters NKCC1 and KCC2 in patients with juvenile myoclonic epilepsy

Recumbent stepping aerobic exercise in amyotrophic lateral sclerosis: a pilot study

L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza’s syndrome

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie